Linvoseltamab (REGN5458) is a fully human BCMA x CD3 bispecific T-cell engaging antibody. This product simultaneously binds to B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells, inducing T-cell directed killing of tumor cells. It plays a significant role in the research of treatment mechanisms for relapsed/refractory multiple myeloma.

In vitro assays, Linvoseltamab (0.1-10 nM) effectively activates NFAT signaling and increases the expression of CD25 in effector cells, demonstrating potent cytotoxicity against BCMA-expressing human plasma cells and multiple myeloma cell lines such as NCI-H929 and MOLP-8 [2].

In pharmacological studies using NCI-H929 or MOLP-8 xenograft mouse models, intravenous administration of Linvoseltamab (0.4-4 mg/kg, twice a week for 7 doses) demonstrated robust anti-tumor activity by significantly inhibiting tumor volume growth in a dose-dependent manner, confirming its efficacy in promoting T-cell mediated clearance of myeloma cells in vivo [2].

Human

Monoclonal

Unconjugated